Clearance Rates
Clearer skin as early as Week 1 for atopic dermatitis
Powerful skin clearance anywhere on the body1
Primary endpoint
vIGA-AD
Success
at Week 4
Secondary endpoint
vIGA-AD Clear/
Almost Clear
at Week 4
2x as many patients achieved vIGA-AD Success at Week 4 with ZORYVE vs vehicle (31% vs 14%)3
More patients
achieved vIGA-AD Success as early as Week 12,3*
Data are pooled analyses of the INTEGUMENT-1 and -2 studies.
vIGA-AD = Validated Investigator Global Assessment-Atopic Dermatitis. vIGA-AD Success = Achievement of a vIGA-AD Score of Clear (0) or Almost Clear (1) and a ≥2-grade improvement from baseline.
Nearly 2x as many patients had Clear or Almost Clear skin at Week 4 with ZORYVE vs vehicle (41% vs 21%)2,3
More patients
achieved Clear/Almost Clear skin as early as Week 12,3*
Secondary Endpoint
Data are pooled analyses of the INTEGUMENT-1 and -2 studies
vIGA-AD = Validated Investigator Global Assessment-Atopic Dermatitis.
BASELINE
vIGA-AD = 3
WEEK 4
vIGA-AD = 1
Actual clinical trial patient
Most patients had improved EASI scores with
ZORYVE monotherapy at Week 44
9 in 10 patients experienced improvements
in clinical signs at Week 42,4
Pooled EASI response rates of the INTEGUMENT-1 and -2 studies. Analysis provides a summary of EASI improvement for every patient in INTEGUMENT-1 and -2. EASI response rates are defined as percentage of patients with improved EASI scores from baseline to Week 4. EASI scores evaluate the following atopic dermatitis symptoms: erythema, skin thickness (induration, papulation, swelling), excoriations, lichenification, and percentage of region affected.2
EASI = Eczema Area and Severity Index. EASI-50 = 50% reduction in EASI score from baseline. EASI-75 = 75% reduction in EASI score from baseline. EASI-90 = 90% reduction in EASI score from baseline. EASI-100 = 100% reduction in EASI score from baseline.
See itch relief data